Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison Between Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo - a Randomized Controlled Trial

NCT06593197 is registered in ClinicalTrials.gov with Dow University of Health Sciences as lead sponsor.

NCT NCT06593197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06593197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison Between Apremilast in Combination with NBUVB and NBUVB Alone in Vitiligo - a Randomized Controlled Trial
Lead sponsor
Dow University of Health Sciences
Phase
Phase 4
Overall status
Enrolling by invitation
Start date
January 1, 2025
Completion date
March 30, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

vitiligo